Precision Medicine in Oncology®

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.

Dr. Roman Perez-Soler, from Albert Einstein College of Medicine, on the Future of Lung Cancer Therapies

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Chandra Belani from Penn State Hershey Cancer Institute Discusses Driver Mutations in NSCLC

Dr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity

Patients who initially exhibit a response to a particular strategy may achieve substantial clinical benefit if the same or very similar agents are delivered after variably defined treatment-free intervals.

Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Targeting Dormant Cancer Cells

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Deirdre Cohen, from NYU Medical Oncology Associates, Addresses the Role of the Hedgehog Pathway

Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

Dr. Deirdre Cohen, NYU Medical Oncology Associates, Discusses Hedgehog Pathway Inhibition

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.